Literature DB >> 11241035

Detection of IgA and IgG but not IgE antibody to respiratory syncytial virus in nasal washes and sera from infants with wheezing.

A De Alarcon1, E E Walsh, H T Carper, J B La Russa, B A Evans, G P Rakes, T A Platts-Mills, P W Heymann.   

Abstract

BACKGROUND AND
OBJECTIVE: The capacity of respiratory syncytial virus (RSV) to stimulate an IgE antibody response and enhance the development of atopy and asthma remains controversial. Nasal washes and sera from 40 infants (20 with wheezing, 9 with rhinitis, and 11 without respiratory tract symptoms) were obtained to measure IgE, IgA, and IgG antibody to the immunodominant, F and G, virion proteins from RSV. STUDY
DESIGN: Children (aged 6 weeks to 2 years) were enrolled in the emergency department during the mid-winter months and seen at follow-up when they were asymptomatic. All nasal washes were tested for RSV antigen. Determinations of antibody isotypes (IgE, IgA, and IgG) to RSV antigens were done in nasal washes and sera by using an enzyme-linked immunosorbent assay. In a subset of nasal washes, IgE to RSV was also evaluated by using a monoclonal anti-F(c)E antibody-based assay.
RESULTS: Fifteen patients with wheezing, two with rhinitis, and one control subject tested positive for RSV antigen at enrollment. Thirteen patients with wheezing were <6 months old, and most (77%) were experiencing their first attack. Among the children with positive test results for RSV antigen, an increase in both nasal wash and serum IgA antibody to RSV-F(a) and G(a) was observed at the follow-up visit. However, there was no evidence for an IgE antibody response to either antigen.
CONCLUSION: Both IgA and IgG antibodies to the immunodominant RSV-F(a) and G(a) antigens were readily detected in the nasal washes and sera from patients in this study. We were unable to demonstrate specific IgE antibody to these antigens and conclude that the production of IgE as a manifestation of a T(H)2 lymphocyte response to RSV is unlikely.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241035     DOI: 10.1067/mpd.2001.111277

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

Review 1.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 2.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

Review 3.  Respiratory viral infections and atopic development: From possible mechanisms to advances in treatment.

Authors:  Lisa M Martorano; Mitchell H Grayson
Journal:  Eur J Immunol       Date:  2018-01-15       Impact factor: 5.532

4.  Evidence of a causal role of winter virus infection during infancy in early childhood asthma.

Authors:  Pingsheng Wu; William D Dupont; Marie R Griffin; Kecia N Carroll; Edward F Mitchel; Tebeb Gebretsadik; Tina V Hartert
Journal:  Am J Respir Crit Care Med       Date:  2008-09-05       Impact factor: 21.405

Review 5.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

Review 6.  Clinical perspectives on the association between respiratory syncytial virus and reactive airway disease.

Authors:  Nele Sigurs
Journal:  Respir Res       Date:  2002-06-24

7.  Cellular and humoral immunity of virus-induced asthma.

Authors:  Yoshimichi Okayama
Journal:  Front Microbiol       Date:  2013-08-27       Impact factor: 5.640

8.  Risk factors for wheezing in a subtropical environment: role of respiratory viruses and allergen sensitization.

Authors:  Ataide A Camara; Jorgete M Silva; Virginia P L Ferriani; Kátia R C Tobias; Izolete S Macedo; Márcio A Padovani; Charlotte M Harsi; M Regina A Cardoso; Martin D Chapman; Eurico Arruda; Thomas A E Platts-Mills; L Karla Arruda
Journal:  J Allergy Clin Immunol       Date:  2004-03       Impact factor: 10.793

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.